|
 |
|
|
|
|
|
|
|
 |
|
Identification of best predictive Biomarkers:
we see more than others ! |
|
 |
Exhaustively identify best subset of markers maximizing patient
coverage and discrimination leading to best predictive power |
|
Easy integration and combination of heterogeneous data including
genomic, proteomic, polypharmacology and clinical data |
|
Robust handling of missing data |
|
Logic based and easy to interpret. System explains results and
identifies knowledge gaps |
|
|
|
Broad range of successful
applications: |
|
|
Discovery: Combination
of molecular structure
and pharmacological
profiling as markers for
clinical Adverse Events |
|
Safety: Surrogate Safety
Biomarkers |
|
Clinical Studies: Efficacy
Biomarkers |
|
Diagnostics and
Prognostics: In-vitro
and in-vivo Biomarkers
(companion markers) |
|
Effective even with
small number of
patients and large
number of descriptors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Boston
One Broadway, 14th Floor
Cambridge MA-02142 - USA
|
ph:+1 617 583 1340
|
Paris
28 rue du Docteur Finlay
75015 Paris - France
|
t: +33 (0)1 44 37 17 00
f: +33 (0)1 44 37 17 01
|
|
|
Send us an email >>
|
|
|
|
|
|
|
|
